Lyka Labs Limited (LYKALABS.BO)
INR 103.05
(0.19%)
INR 103.05
(0.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -24.89 Million INR | 81.16% |
| 2022 | -132.11 Million INR | -133.88% |
| 2021 | 389.99 Million INR | 437.53% |
| 2020 | -115.54 Million INR | 80.91% |
| 2019 | -605.41 Million INR | -990.78% |
| 2018 | -55.5 Million INR | 67.87% |
| 2017 | -172.74 Million INR | -211.92% |
| 2016 | -55.38 Million INR | -250.22% |
| 2015 | 36.86 Million INR | 174.49% |
| 2014 | -49.49 Million INR | 24.89% |
| 2013 | -65.89 Million INR | -831.11% |
| 2012 | -7.07 Million INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 24.1 Million INR | 149.59% |
| 2009 | -48.62 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 14.4 Million INR | 167.68% |
| 2023 Q4 | -21.27 Million INR | -219.47% |
| 2023 Q3 | 17.81 Million INR | 466.08% |
| 2023 Q2 | -4.86 Million INR | 73.66% |
| 2023 Q1 | -18.46 Million INR | 38.59% |
| 2023 FY | -24.89 Million INR | 81.16% |
| 2022 FY | -132.11 Million INR | -133.88% |
| 2022 Q4 | -30.07 Million INR | 71.13% |
| 2022 Q3 | -104.15 Million INR | -2613.89% |
| 2022 Q2 | -3.83 Million INR | -164.47% |
| 2022 Q1 | 5.95 Million INR | 103.95% |
| 2021 FY | 389.99 Million INR | 437.53% |
| 2021 Q2 | 284.33 Million INR | 45.43% |
| 2021 Q4 | -150.7 Million INR | -347.63% |
| 2021 Q1 | 195.5 Million INR | 1622.68% |
| 2021 Q3 | 60.85 Million INR | -78.6% |
| 2020 FY | -115.54 Million INR | 80.91% |
| 2020 Q1 | -46.74 Million INR | 63.98% |
| 2020 Q2 | -57.49 Million INR | -22.99% |
| 2020 Q3 | -22.65 Million INR | 60.6% |
| 2020 Q4 | 11.34 Million INR | 150.1% |
| 2019 Q2 | -32.03 Million INR | -1.2% |
| 2019 Q4 | -129.77 Million INR | 68.5% |
| 2019 Q3 | -411.95 Million INR | -1186.04% |
| 2019 FY | -605.41 Million INR | -990.78% |
| 2019 Q1 | -31.65 Million INR | -140.66% |
| 2018 Q1 | -56.05 Million INR | 0.0% |
| 2018 FY | -55.5 Million INR | 67.87% |
| 2018 Q4 | 77.83 Million INR | 357.87% |
| 2018 Q3 | -30.18 Million INR | 53.25% |
| 2018 Q2 | -64.56 Million INR | -15.19% |
| 2017 FY | -172.74 Million INR | -211.92% |
| 2016 Q1 | -41.36 Million INR | 60.46% |
| 2016 Q2 | 4.97 Million INR | 112.03% |
| 2016 Q3 | -28.78 Million INR | -678.24% |
| 2016 Q4 | 18.41 Million INR | 163.98% |
| 2016 FY | -55.38 Million INR | -250.22% |
| 2015 Q3 | 5.36 Million INR | -96.04% |
| 2015 Q2 | 135.32 Million INR | 703.1% |
| 2015 FY | 36.86 Million INR | 174.49% |
| 2015 Q1 | 16.85 Million INR | 161.08% |
| 2015 Q4 | -104.62 Million INR | -2051.31% |
| 2014 Q3 | -58.83 Million INR | -192.76% |
| 2014 Q2 | 63.42 Million INR | 168.61% |
| 2014 Q1 | -92.44 Million INR | 0.0% |
| 2014 FY | -49.49 Million INR | 24.89% |
| 2014 Q4 | -27.58 Million INR | 53.11% |
| 2013 Q1 | -24.66 Million INR | 66.86% |
| 2013 Q3 | -95.37 Million INR | -215.25% |
| 2013 FY | -65.89 Million INR | -831.11% |
| 2013 Q2 | -30.25 Million INR | -22.66% |
| 2012 Q4 | -74.42 Million INR | -238.6% |
| 2012 Q3 | 53.69 Million INR | 1195.42% |
| 2012 Q2 | 4.14 Million INR | -56.41% |
| 2012 FY | -7.07 Million INR | 0.0% |
| 2012 Q1 | 9.5 Million INR | 0.0% |
| 2011 Q3 | -22.99 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2010 FY | 24.1 Million INR | 149.59% |
| 2009 FY | -48.62 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 2.76 Million INR | 1000.651% |
| Biocon Limited | 10.22 Billion INR | 100.243% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | 101.52% |
| Concord Biotech Limited | 3.08 Billion INR | 100.808% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 98.378% |
| FERMENTA BIOTECH LIMITED | -230.59 Million INR | 89.205% |
| GENOMIC VALLEY BIOTECH LIMITED | 151.81 Thousand INR | 16497.265% |
| Panacea Biotec Limited | -11.73 Million INR | -112.225% |
| SAMSRITA LABS LIMITED | -2.62 Million INR | -849.265% |
| Servoteach Industries Limited | -2.37 Million INR | -948.61% |
| SMS Lifesciences India Limited | 90.92 Million INR | 127.378% |
| Supriya Lifescience Limited | 1.19 Billion INR | 102.09% |
| Syngene International Limited | 5.1 Billion INR | 100.488% |
| TAKE Solutions Limited | -1.19 Billion INR | 97.919% |
| Titan Biotech Limited | 248.53 Million INR | 110.016% |
| Transgene Biotek Limited | -6.55 Million INR | -279.771% |
| Vanta Bioscience Limited | -23.15 Million INR | -7.492% |